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2Abstract
Introduction: Current guidelines recommend regular follow-up in coeliac disease, but effect of
this on long-term health outcomes remains unclear.
Aims: To evaluate predictors and significance of long-term follow-up
Methods: Altogether 677 previously diagnosed coeliac disease patients were recruited for a
nationwide health survey. Medical data were gathered through interviews and patient records.
Current symptoms and quality of life were assessed by validated questionnaires and blood
samples were drawn for serology. All variables were compared between patients with and
without long-term (>2 years) follow-up.
Results: Only 15% had long-term follow-up, median duration 10 years. Predictors (p<0.05) for
the follow-up were immunological (35% vs. 24%) and circulatory (20% vs. 12%)
comorbidities, whereas it was less common in subjects with musculoskeletal (23% vs. 34%)
comorbidity and those not belonging to any at-risk group (16% vs. 27%). Patients with or
without follow-up had comparable age, adherence and ability to manage a gluten-free diet and
frequency of seropositivity. Also questionnaire scores paralleled, but those without follow-up
reported more overall symptoms (16% vs. 26%). Most patients in both groups wished for
follow-up.
Conclusion: Only a minority of patients had regular follow-up. However, patients with and
without the follow-up were comparable in most long-term outcomes, indicating that it might
not be always necessary. The results call for more personalized follow-up policies in coeliac
disease.
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3Introduction
Coeliac disease is a lifelong gluten-induced autoimmune enteropathy with a prevalence up to
2% in Caucasian populations (1). The only treatment is a strict gluten-free diet, the initiation of
which usually elicits a clear clinical and histological response and disappearance of the disease-
specific autoantibodies (2). Unfortunately, the high cost and restrictive nature of the gluten-free
diet predisposes to poor adherence and subsequently to persistent enteropathy and an increased
risk of serious complications such as osteoporotic fractures and malignancy (3-6). Moreover,
there is a subgroup of patients with a condition called refractory coeliac disease, who do not
attain adequate clinical and histological recovery despite a strict diet and thus have particularly
poor prognosis (7).
In order to ensure proper adherence and response to the gluten-free diet and to detect
possible complications, most current guidelines recommend regular long-term follow-up in
coeliac disease even as often as annually (2, 8). However, there is a paucity of evidence as to
how the follow-up is actually implemented in clinical practice, and whether the absence of
follow-up really affects the long-term coping and health of the patients (9-15). Interestingly, in
a 15-year follow-up we recently found that the lack of a repeat biopsy one year after coeliac
disease diagnosis is not associated with an increased risk of adverse outcomes such as reduced
well-being or malignancies (16). This would indicate that the association between the presence
of follow-up and the prognosis of coeliac disease is more complex than one might expect.
To further elucidate the significance of regular follow-up to the treatment success
in coeliac disease, we conducted a nationwide survey and compared various patient-related and
other relevant factors between large cohorts of coeliac disease patients with or without long-
term follow-up after diagnosis.
Materials and Methods
4Patients and study design
A nationwide cross-sectional health survey was conducted in Tampere University Hospital and
the University of Tampere. The survey was created to investigate variable aspects of coeliac
disease, not just factors associated with the long-term follow-up. The participants were
recruited through newspaper advertisements and with the aid of coeliac disease societies.
Inclusion criteria were age ≥18 years and a biopsy-proven diagnosis at least two years before
enrolment. All participants filled validated questionnaires on current symptoms and quality of
life and were interviewed systematically by a physician or a study nurse with expertise in
coeliac disease. Patients unable to attain the study center were interviewed by phone and
questionnaires were sent by mail. Patient records were reviewed in order to confirm the
diagnosis and to complement medical data. In addition, blood samples were drawn for
serological measurements, in case of phone interviews this was done at the nearest laboratory.
Subjects with dermatitis herpetiformis were excluded owing to their different diagnostic and
follow-up protocol, as well as patients with an unclear diagnosis or substantially incomplete
medical information. Altogether 677 participants, representing approximately 2% of the whole
Finnish coeliac population (4), were enrolled for further analyses.
After data collection the results were analyzed between subgroups of participants
who either had or had not been systematically and regularly assessed for at least two years after
the diagnosis by health care for dietary compliance and treatment success. This sorting was
based on the patients´ own reporting and medical record data. Also possible coeliac disease
controls carried out during health care visits for other conditions were included. Subgroup
analyses were carried out in patients with only a short-term follow-up (<2 years) and those
without any follow-up. The findings were compared with our national recommendations. In
Finland, the follow-up of coeliac disease is decentralized to primary care, with the general
practitioners in charge. If needed, the patient can be referred to a specialist in a reasonable time
5frame. To unify diagnostics and treatment, there are national Current Care Guidelines, which
recommend a repeat biopsy one year after diagnosis and regular clinical and serological follow-
up at 2-3-year intervals (Collin 2010).
Patient enrolment and collection of study data were conducted with the
permission and according to the guidelines of the Ethical Committee of the Pirkanmaa Hospital
District. All participants gave written informed consent.
Clinical characteristics
The clinical information collected included demographic data, the type and the severity of
clinical presentation before diagnosis, duration of symptoms and their current self-experienced
persistence. Family history of coeliac disease, presence of coeliac disease-associated and other
significant chronic comorbidities were also inquired. The latter included particularly
immunological (e.g. asthma, allergies), circulatory (e.g. hypertension, coronary artery disease)
and musculoskeletal (e.g. arthritis, fibromyalgia) conditions. Current or previous smoking and
whether the coeliac disease diagnosis was made in primary, secondary or tertiary public care or
in private care were also inquired. The self-perceived severity of clinical presentation was asked
to estimate the burden of symptoms. These were further classified into 1) no symptoms; 2) mild
symptoms such as occasionally disturbing gastrointestinal or extra-intestinal symptoms or a
combination of them and 3) severe symptoms seriously disturbing daily life, such as recurrent
awakenings because of pain or symptoms requiring acute inpatient care (17).
Small-bowel mucosal biopsies
Data on small-bowel mucosal biopsies were collected from the patient records. Our national
diagnostic guidelines for coeliac disease recommend at least four duodenal biopsies to be taken
routinely from each patient upon coeliac disease suspicion and during the possible repeat
6endoscopy after one year on a gluten-free diet. The histological specimens are forwarded to the
hospitals’ pathology department, where the severity of mucosal damage is evaluated in
representative and correctly orientated biopsy cuttings. Demonstration of duodenal villous
atrophy is required for celiac disease diagnosis. The degree of mucosal lesion has for decades
been graded as partial, subtotal or total villous atrophy, these corresponding approximately
grades 3a, 3b and 3c in Marsh-Oberhuber classification.
Celiac disease serology
Values for serum endomysial antibodies (EmA) at diagnosis were gathered from patient
records. Furthermore, EmA and transglutaminase 2 antibodies (TG2ab) were measured in all
patients at the time of the current study. Indirect immunofluorescence was used for EmA
measurements as previously described (18). Titers 1: ≥5 were considered positive and diluted
until negative to 1:50, 1:100, 1:200, 1:500, 1:1000, 1:2000 and 1:4000. These were further
classified as low (1:5-1:200) and high positive (1:500-1:4000). TG2ab were tested by
commercial ELISA (QUANTA Lite h-tTG IgA, INOVA Diagnostics, San Diego, CA),
considering a cut-off >30.0 U/l positive. Corresponding IgG-class antibodies were measured in
cases of selective IgA deficiency.
Adherence to the gluten-free diet
Provision of dietary advice at coeliac disease diagnosis was verified by patient interview and
from patient records. Current long-term dietary adherence was also inquired by an experienced
study nurse/physician with an expertise in coeliac disease and classified as “strict” (minor
inadvertent lapses less than a few times a year), “occasional lapses” (lapses less often than once
per month) and “normal diet”. Long-term adherence was further estimated on the basis of
7coeliac antibody positivity at the time of the present study. Alongside adherence, patient’s
overall competency in managing the diet and the possible use of purified oats was asked.
Questionnaires
Short Form 36 Health Survey (SF-36) and Psychological General Well-Being questionnaires
(PGWB) were used to assess patients’ current self-perceived quality of life and gastrointestinal
symptoms at time of study.
SF-36 comprises 36 separate questions, divided into eight sub-dimensions as
follows; physical functioning, role limitations due to physical problems, bodily pain, general
health, vitality, social functioning, role limitations due to emotional problems and mental health
(19-23). Items are re-scored from 0 to 100, higher scores indicating better health and quality of
life.
PGWB is a well-validated and widely used questionnaire both in coeliac disease
and in general (18, 20, 22, 23). The 22 separate items can be further divided into six sub-
dimensions measuring anxiety, depression, well-being, self-control, general health and vitality.
All items use a 6-grade Likert scale with higher scores representing better well-being and
quality of life.
Gastrointestinal symptoms were evaluated by the Gastrointestinal Symptom Rating
Scale (GSRS) questionnaire (18, 24). It includes 15 separate items which can be added together
as a total score and further divided into 5 sub-dimensions measuring abdominal pain, gastro-
esophageal reflux, indigestion, diarrhea and constipation. The scoring is based on a 7-grade
Likert scale, higher scores reflecting more severe gastrointestinal symptom.
Statistical analysis
8Continuous variables are presented as medians with quartiles or ranges. Categorical variables
are presented as number of subjects and percentages. Statistical significance in differences
between patients with and without long-term follow-up was studied using Mann-Whitney test.
Binominal and classified variables were analyzed using Chi-square test. A p-value <0.05 was
considered significant in all analyses. All analyses were carried out using SPSS 20.0 (IBM
Corp. Armonk, NY).
Results
The median age of the whole study cohort was 44 (range 22-89) years and 80% were women.
The median follow-up time for the whole study group was 10 (range 2-38) years. Out of the
677 participants, 99 (15%) had and 578 (85%) had not received long-term follow-up for coeliac
disease.
Factors predicting long-term follow-up
Existence of follow-up was predicted by the presence of immunological (35% vs 24%, p=0.020)
and circulatory (20% vs. 12%, p=0.010) comorbidities, whereas it was less common in subjects
with coexisting musculoskeletal disease (23% vs. 34%, p=0.045). Those not belonging to any
at-risk group, such as patients with type I diabetes and those with family history for coeliac
disease, were more likely to be without follow-up (Table 1). In contrast, follow-up was not
predicted by other co-morbidities (data not shown), gender, site of diagnosis, seropositivity for
celiac autoantibodies or severity of histological lesion at diagnosis, symptoms in childhood,
clinical presentation or duration of symptoms before diagnosis, family risk of coeliac disease
or associated condition and smoking (Table 1). Also age at diagnosis (median 42 vs. 44 years,
range 18-75 vs. 18-71 years, p = 0.117) or at present (median 54 vs. 54 years, range 22-81 vs
921-89 years, p = 0.919) did not significantly differ between patients with and without follow-
up.
When looking into the short-term clinical characteristic one year after diagnosis of
those patients the data was available, there was no significant association between the presence
coeliac autoantibody positivity (6.3% vs. 15.1%, respectively p=0.343; n=95) between groups.
Neither did the groups differ in the prevalence of histological recovery (fully normalized 53.0%
vs. 60.2%, p=0.378; n=398) in the follow-up and no-follow up groups after one year on a gluten-
free diet and existence of long-term follow.
Long-term outcomes in patients with and without follow-up
Participants in both follow-up and no-follow up groups had similar dietary adherence and ability
to manage the gluten-free diet, as well as use of purified oats (Table 2). There was also no
difference between the groups in current positivity for coeliac autoantibodies (Table 2) or in
any of the questionnaire scores measuring health-related quality of life (SF-36, PGWB) and
gastrointestinal symptoms (GSRS) (Table 3). However, patients without regular long-term
follow-up suffered more from current self-reported overall symptoms (Table 2). Despite this
difference in significance, there was a correlation between self-reported symptoms and those
evaluated by GSRS.  Nevertheless, patients with more indigestion, reflux, constipation and
abdominal pain in GSRS are more likely to report more severe self-perceived symptoms. In
contrast, the amounts of diarrhea and constipation were not associated with the severity of self-
perceived symptoms (Data not shown)
Altogether 98 % of patients with regular long-term follow-up wished for it also in
the future, and this was also seen in over 80% of the patients of patients not currently under
follow-up (Table 2). Most of these patients wished the follow-up to be organized in public
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healthcare (Figure 1), whereas there was no major difference regarding who should be in charge
of the follow-up (Figure 2).
Sub-analysis of patients without any follow-up and short-term follow-up
Altogether 84 (12%) out of the 677 participants had not received any follow-up for coeliac
disease after the diagnosis, while 465 (69%) had been subject only to short-term follow-up (<2
year). Compared to patients receiving long-term follow-up, patients without any follow-up had
more current mild symptoms (27% vs. 13% p = 0.038). Furthermore, those without any follow-
up had fewer circulatory diseases (18% vs. 35%, respectively, p = 0.009) and a lower desire for
regular follow-up (85% vs. 92%, p = 0.024) than those with long-term follow-up.
Discussion
We found the prevalence of regular follow-up to be only 15% in Finnish coeliac disease patients
(16). This is in stark contrast to our national guidelines that recommend regular long-term
clinical and serological follow-up in all patients (Collin 2010). It is also a markedly lower
percentage than reported previously. In the early 1990s Bardella et al. (25) reported a follow-
up rate of 77%. Bebb et al. found the corresponding figure to be 62%, although only 6% of the
patients later transferred to primary care received follow-up (26). In a study by Herman et al.
41% of patients received a follow-up during the first year after, this percentage increasing to
89% after five years (11). The results by Bardella et al. could be affected by the fact that the
patients were investigated during their transition from pediatric to adult care, at which time at
least one visit is often scheduled. Another explanation for the different percentages could be
related to our practice to refer coeliac disease patients in primary care soon after the diagnosis,
whereas most of the previous studies were carried out in tertiary centers. We must, however,
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emphasize that also the majority of our patients received short-term follow-up, including a
follow-up biopsy one year after the diagnosis (16).
There are also further explanations why the long-term follow-up frequency is low
particularly in Finland. Most of the patients have only mild symptoms, reflecting the short
diagnostic delay and good recognition of the disease by physicians (27). This, along with the
good dietary adherence, has made severe complications associated with advanced or poorly
treated coeliac disease rare (4). As a result, demonstration of initial treatment response might
often be deemed sufficient by physicians. From patients’ perspective, they may find it hard to
motivate themselves to seek for healthcare visits when the disease does not constitute a
substantial daily burden. In Finland public healthcare is accessible equally to all citizens, further
indicating that the patients themselves have not contacted the healthcare services. We believe
that patients would have received a follow-up if actively seeking it. Thus, it is likely that, even
if patients would “like” to have a follow-up, they do not actively seek it if not organized by the
health care. In these circumstances, a more active role of the healthcare providers might be
required to improve attendance in follow-up (28).
One of the main arguments for follow-up in coeliac disease is the need to monitor
dietary adherence. It was thus of significance that also patients without follow-up reported
excellent adherence and competence to maintain a gluten-free diet. This was supported by the
low frequency of current coeliac antibody positivity, although it must be realized that serology
has limited sensitivity in the detection of dietary lapses (3). The higher prevalence of
seropositivity over against self-reported adherence could be caused by unrecognized lapses or
via the slow normalization of high values. (13, 29-31).  Previously Bardella et al. found regular
follow-up to improve adherence in adults (13) and Barnea et al. reported similar finding in
children (29). The absence of such an association in Finland could be due to the high prevalence
of the disease and good availability of gluten-free products, and the widespread knowledge of
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coeliac disease among physicians and food industry. We also wish to emphasize that previously
all Finnish patients received governmental reimbursement for dietary expenses (ended in 2016).
Owing to these particularities, our results may not be directly applicable to countries in which
coeliac disease is rarer and less well known.
The majority of patients were satisfied that the follow-up was arranged by general
practitioners, although one third would prefer visits to a specialist. This is in line with the strong
public healthcare sector in Finland and a long tradition of decentralization in coeliac disease
follow-up. This aspect has not been studied using a similar approach, but Bebb et al. (26) found
the preferred method for follow-up to be visits to a dietician with a possibility to consult a
physician. We find such a dietician-led clinic an interesting alternative, as dietary lapses are the
most common reason for non-response in coeliac disease, even in apparently compliant subjects
(32). However, this approach would likely provide no major benefits in well-doing and strictly
adherent patients. Anyhow, the possible need for patients with persistent symptoms to consult
a physician should be taken into account in these circumstances.
Although most of the long-term outcomes were comparable between the study
groups, patients without follow-up felt they had more current symptoms when asked as a
qualitative estimation. We recently found persistent symptoms to be common even in well-
treated coeliac disease (33), but no studies have looked into the association between ongoing
symptoms and lack of follow-up. Interestingly, the difference in symptoms disappeared when
evaluated by a validated questionnaire, indicating that the direct question emphasizes the
subjective experience rather than the objective magnitude of symptoms. Other explanation for
the results is that GSRS measures a wide scale of even opposing symptoms such as diarrhea
and constipation. Gastrointestinal symptoms are common and not always necessarily related to
coeliac disease. In fact, the median GSRS scores in our treated celiac disease patients were
comparable to the Finnish population (33). It might be that regular healthcare contacts improve
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sense of self-capability and reduce excessive monitoring of symptoms. Accordingly, patients
with irritable bowel syndrome have benefited from physicians’ reassurance on the benignity of
their symptoms (34, 35).
Strength of the present study was the large number of patients diagnosed on
different levels of healthcare. We also succeeded in collecting a wide variety of clinically
relevant parameters, and the use of validated questionnaires increases the reliability of results.
As a limitation, patient recruitment by newspaper advertisements and via celiac societies
predisposes to selection bias. For example, the study information might have reached different
age groups and socioeconomic classes unequally. Furthermore, although not specifically
designed as a follow-up study, patients without regular follow-up could have considered our
survey as an “extra visit” and thus have been more eager to participate. Additional study
limitations were the lack of data on the patients’ socio-economic status (30, 36), scarcity of
short-term serological follow-up data and the use of inexact three-point scale in the evaluation
of self-reported symptoms. The cross-sectional design also prevented us from evaluating the
causality in for example the incidence of comorbidities.
In conclusion, we found follow-up in coeliac disease not to meet the current
recommendations. However, the necessity for rigid follow-up scheme could be questioned, as
there was no difference between the study groups in most long-term health outcomes. These
findings call for more a personalized approach: patients achieving clear remission could visit
healthcare only if symptoms reappear or after major life changes, whereas those facing more
challenges might benefit from more systematic follow-up.
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Figure legends
Figure 1: Patients’ opinion on where the long-term follow-up of celiac disease should be
organized, divided on basis of the lack (No follow-up) or presence (Follow-up) of current
regular follow-up.
Figure 2. Patients’ opinion on who should be in charge of the long-term follow-up of celiac
disease, divided on basis of the lack (No follow-up) or presence (Follow-up) of current
regular follow-up.
